http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017209408-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a06ec984f84159c25f624614131954e9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate | 2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9339eb78460afb759fbd34dba16d74b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e5b05669f1faea3564c8ec18c200093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4faab19a71d832c80ba7e290d082c39d |
| publicationDate | 2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2017209408-A1 |
| titleOfInvention | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| abstract | HSP 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical compositions can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof. In particular embodiments, the weight loss agent is co-administered with leptin or a leptin analog. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111973755-A |
| priorityDate | 2014-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 345.